| 1 |
Sampson C, Wang Q, Otkur W, Zhao H, Lu Y, Liu X, Piao HL. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin Transl Med 2023;13:e1204. [PMID: 36881608 DOI: 10.1002/ctm2.1204] [Reference Citation Analysis]
|
| 2 |
Iacopetta D, Ceramella J, Baldino N, Sinicropi MS, Catalano A. Targeting Breast Cancer: An Overlook on Current Strategies. Int J Mol Sci 2023;24. [PMID: 36835056 DOI: 10.3390/ijms24043643] [Reference Citation Analysis]
|
| 3 |
López LS, Calvo EP, Castellanos JE. Deubiquitinating Enzyme Inhibitors Block Chikungunya Virus Replication. Viruses 2023;15. [PMID: 36851696 DOI: 10.3390/v15020481] [Reference Citation Analysis]
|
| 4 |
Abramson HN. Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. Int J Mol Sci 2023;24. [PMID: 36768967 DOI: 10.3390/ijms24032645] [Reference Citation Analysis]
|
| 5 |
Asano Y, Matsumoto Y, Wada J, Rottapel R. E3-ubiquitin ligases and recent progress in osteoimmunology. Front Immunol 2023;14:1120710. [PMID: 36911671 DOI: 10.3389/fimmu.2023.1120710] [Reference Citation Analysis]
|
| 6 |
Shi J, Guo Y, Wang H, Xiao Y, Liu W, Lyu L. The ubiquitin-proteasome system in melanin metabolism. J Cosmet Dermatol 2022;21:6661-8. [PMID: 36207998 DOI: 10.1111/jocd.15433] [Reference Citation Analysis]
|
| 7 |
Montagut AM, Armengol M, de Pablo GG, Estrada-Tejedor R, Borrell JI, Roué G. Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer. Semin Cell Dev Biol 2022;132:213-29. [PMID: 35184940 DOI: 10.1016/j.semcdb.2022.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Li Q, Zhang W. Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors. Int J Mol Sci 2022;23. [PMID: 36499442 DOI: 10.3390/ijms232315104] [Reference Citation Analysis]
|
| 9 |
Vamisetti GB, Saha A, Huang YJ, Vanjari R, Mann G, Gutbrod J, Ayoub N, Suga H, Brik A. Selective macrocyclic peptide modulators of Lys63-linked ubiquitin chains disrupt DNA damage repair. Nat Commun 2022;13:6174. [PMID: 36257952 DOI: 10.1038/s41467-022-33808-6] [Reference Citation Analysis]
|
| 10 |
Zeng R, Xiong Y, Lin Z, Panayi AC, Sun Y, Cao F, Liu G, Deng R. E3 Ubiquitin Ligases: Potential Therapeutic Targets for Skeletal Pathology and Degeneration. Stem Cells International 2022;2022:1-13. [DOI: 10.1155/2022/6948367] [Reference Citation Analysis]
|
| 11 |
Verzella D, Cornice J, Arboretto P, Vecchiotti D, Di Vito Nolfi M, Capece D, Zazzeroni F, Franzoso G. The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target. Biomedicines 2022;10. [PMID: 36140335 DOI: 10.3390/biomedicines10092233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Jiang L, He Q, Chen X, Liu A, Ding W, Zhang H, Chen X, Zhou H, Meng Y, Liu B, Peng G, Wang C, Liu J, Shi X. Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia. Clin Transl Med 2022;12:e1038. [PMID: 36082692 DOI: 10.1002/ctm2.1038] [Reference Citation Analysis]
|
| 13 |
Huang T, Li J, Liu X, Shi B, Li S, An H. An integrative pan-cancer analysis revealing the difference in small ring finger family of SCF E3 ubiquitin ligases. Front Immunol 2022;13:968777. [DOI: 10.3389/fimmu.2022.968777] [Reference Citation Analysis]
|
| 14 |
Drula R, Iluta S, Gulei D, Iuga C, Dima D, Ghiaur G, Buzoianu AD, Ciechanover A, Tomuleasa C. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. Blood Rev 2022;:100971. [PMID: 35595613 DOI: 10.1016/j.blre.2022.100971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Gubat J, Selvaraju K, Sjöstrand L, Kumar Singh D, Turkina MV, Schmierer B, Sabatier P, Zubarev RA, Linder S, D’arcy P. Comprehensive Target Screening and Cellular Profiling of the Cancer-Active Compound b-AP15 Indicate Abrogation of Protein Homeostasis and Organelle Dysfunction as the Primary Mechanism of Action. Front Oncol 2022;12:852980. [DOI: 10.3389/fonc.2022.852980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Bano I, Malhi M, Zhao M, Giurgiulescu L, Sajjad H, Kieliszek M. A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy. 3 Biotech 2022;12:103. [PMID: 35463041 DOI: 10.1007/s13205-022-03162-x] [Reference Citation Analysis]
|
| 17 |
Tu R, Ma J, Zhang P, Kang Y, Xiong X, Zhu J, Li M, Zhang C. The emerging role of deubiquitylating enzymes as therapeutic targets in cancer metabolism. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02524-y] [Reference Citation Analysis]
|
| 18 |
Zhong Y, Chi F, Wu H, Liu Y, Xie Z, Huang W, Shi W, Qian H. Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond. European Journal of Medicinal Chemistry 2022;231:114142. [DOI: 10.1016/j.ejmech.2022.114142] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 19 |
Celesia A, Fiore T, Di Liberto D, Giuliano M, Pellerito C, Emanuele S. Bortezomib potentiates the antitumor effect of tributyltin(IV) ferulate in colon cancer cells exacerbating ER stress and promoting apoptosis. Inorganica Chimica Acta 2022. [DOI: 10.1016/j.ica.2022.120929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Zhang YY, Peng J, Luo XJ. Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases. Biochem Pharmacol 2022;:114977. [PMID: 35218741 DOI: 10.1016/j.bcp.2022.114977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Staszczak M. Fungal Secondary Metabolites as Inhibitors of the Ubiquitin-Proteasome System. Int J Mol Sci 2021;22:13309. [PMID: 34948102 DOI: 10.3390/ijms222413309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 22 |
George DE, Tepe JJ. Advances in Proteasome Enhancement by Small Molecules. Biomolecules 2021;11:1789. [PMID: 34944433 DOI: 10.3390/biom11121789] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Ye P, Chi X, Cha JH, Luo S, Yang G, Yan X, Yang WH. Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges. Cells 2021;10:3309. [PMID: 34943817 DOI: 10.3390/cells10123309] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 24 |
Gavali S, Liu J, Li X, Paolino M. Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy. Int J Mol Sci 2021;22:10800. [PMID: 34639141 DOI: 10.3390/ijms221910800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
